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Systemic lupus erythematosus (SLE: lupus) is a chronic complicated autoimmune disease and pathogenesis is still unclear.
However, key cytokines have been recognized. Interferon (IFN)-γ a n da l s oI F N α/β are of particular importance. Depending
on the concept that lupus is a helper T(Th)1 disease and that dendritic cells (DCs) determine the direction of lupus, balance
shift of Th1/Th2 and immunogenic/tolerogenic DCs is reviewed for therapy. (IFN)-γ-a n dI F N - α/β-targeted (gene) therapies are
introduced. These consist of Th1/Th2 balance shift and elimination of IFN-γ and IFN-γ-related cytokines such as (interleukin)IL-
12 and IL-18. Other approaches include suppression of immunocompetent cells, normalization of abnormal T-cell function,
costimulation blockade, B lymphocyte stimulator (Blys) blockade, and suppression of nephritic kidney inﬂammation. Moreover,
balance shift of IFN-α/β and tumor necrosis factor (TNF)-α together with regulatory T(Treg) cells are briefely introduced. Clinical
application will be discussed.
1.Introduction
Systemic lupus erythematosus (SLE or lupus) is a disorder of
immune regulation characterized by the breakdown of self-
tolerance. The complexities of various humoral and cellular
abnormalities under the inﬂuence with predisposing genetic,
sex hormonal and environmental factors have been reported
in pathogenesis of SLE in human and model animals [1,
2]. In general, patients with overt disease will be treated
with immunosuppressants (e.g., prednisolone, cyclophos-
phamide, and tacrolimus) or NSAIDs (nonsteroidal anti-
inﬂammatory drugs). Those immunosuppressive drugs are
strongly eﬀective in prevention of the development of lupus
nephritis due to reducing the host immune responses.
However, less toxic approaches to avoid severe adverse
events (infections, infertility, amenorrhea, and metabolic
abnormalities) are remained [3, 4]. Thus, there are a lot
of trialsfocusing on improved therapy compared to classic
immunosuppressive drugs in experimental basis [5].
Amoura et al. [6]h a v er e c e n t l yr e v i e w e dn e wb i o -
therapies that new approaches in human lupus are based
on a better understanding of the autoimmune response
as follows. Targets of these new treatments are all steps
of the immune response in lupus development. These are
(1) “B lymphocyte (BL)” inhibitors such as anti-CD20
monoclonal antibody, anti-CD22 monoclonal antibody, B-
lymphocyte stimulator (BlyS) antagonists, tolerogenic pep-
tide [hCDR1: Edratide, which is based on the sequence
of the complementary-determining region (CDR)1 of a
human anti-DNA monoclonal antibody that bears the major
idiotype designated 16/6Id] [7], and LJP 394 (abetimus
sodium) which selectively reduces antibodies to dsDNA
and their parent B cells via antigen-speciﬁc tolerance [1];
(2) “Inhibitors of the costimulation” between antigen-
presentingcellsandTlymphocytebymonoclonalanti-CD40
ligand antibody or CTLA-4-Ig; (3) “Cytokine antagonists”
inhibiting key cytokines of SLE: IL-10 [8], interferon (IFN)-
α [9], which are associated with lupus in human [10], IL-6
[11] and tumor necrosis factor (TNF)-α [12]. In addition,
theimportanceofIL-23/IL-17axisinhumanlupusandlupus
model mice is pointed out [13, 14] and the possibility of IL-
17 targeted therapy is recently proposed since its important2 Journal of Biomedicine and Biotechnology
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Figure 1: Class-switcing of immunoglobulin. Cognate contact of T-B interaction and following stimulation of cytokines determine Ig
subclass switching in mouse.
role in human SLE [4]. Steinmetz et al. [15] showed for
the ﬁrst time that not only Th1, but also Th17 eﬀector T
cells mediate glomerulonephritis in lupus model MRL/lpr
mice.Theyshowedthatdeﬁciencyofthechemokinereceptor
CXCR3-bering T cells (highly expressed on Th1 cells) leads
to signiﬁcant morphological and functional improvement of
nephritic kidneys. Thus, all of those are expected as an eﬀec-
tive new therapy in lupus-like tumor necrosis factor (TNF)-
α targeted therapy in clinical application for rheumatoid
arthritis (RA) [7, 16]. Obviously, eﬀectiveness is reported
by the treatment of anti-IL10 mAb [8], LJP 394 [17],
Edratide[7],inhibitionofTcellcostimulation[18]andanti-
IFN α/β [19] in human lupus. On the other hand, Mohrs
et al. [20] have reviewed that fusion proteins, peptides, and
small molecules rather than therapeutic antibodies which
are excellent alternative tools for immune intervention in
lupus.
Alternatively, immune regulation forming cytokine net-
works including intracellular signaling of cytokines is highly
complex and the mechanisms of regulation is not as yet
fully understood in lupus pathogenesis [21, 22]. Moreover,
compared to organ-speciﬁc autoimmune diseases, several
organs/tissues (e.g., Kidneys, lungs, joints, nervous systems,
and serous membranes) are involved in SLE. Also, patients
with SLE were often accompanied with secondary S¨ ogren’s
syndrome(sSjS)[23].Ineachorganinvolved,pathogenesisis
quite diﬀerent. For example, humoral immunity plays a role
in capillary damages in glomeruli, lungs, dermal tissues [24]
and other organs whereas cell-mediated immunity develops
in interstitium of kidneys, lacrimal, and salivary glands in
lupus with sSjS, resulting in damages of those organs [25].
These suggest that therapy focusing on one cytokine (or
combinationofseveralcytokines)oroneimmunocompetent
cell seems to be diﬃcult. Thus, the concept is very important
by cytokine targeted therapy.
Blocking a single cytokine might be the best to control
this clinically heterogeneous disease in lupus. Depending
on the concept of balance shift, this review introduces [I]
alteration of the balance between Th1(IFN-γ)a n dT h 2c e l l
(IL-4) activity [28, 29]( Figure 1), but not shift proinﬂam-
matory versus immunosuppressive cytokine proﬁles (IL-
1, IL-6, IL-10, TNF-α) and [II] shift from immunogenic
(IFN-α/β) to tolerogenic (TNF-α)D C s( Figure 2) in lupus-
prone mice. Moreover, informative data are involved in
section [I], despite those are diﬀerent from the concept. The
clinical implications including usefulness and unfavorable
side eﬀects in those therapies are discussed in each section.
[I] Th1/Th2 Balance Shift
[1] Lupus is a Th1-Dominant Disease. Several cytokines and
chemokines are involved in the lupus pathogenesis [13, 30]
as described above. More than 30 years ago, Hooks et al.
[31]foundimmuneinterferon(IFN-γ)intheseraofpatients
with SLE and showed a good correlation between immune
IFN-γ titers and disease activity. Moreover, IFN-γ titers
correlated positively with antibodies to DNA and negatively
with serum levels of third components of complement. After
that, however, the dominance of Th1 or Th2 cytokines
in SLE patients and lupus model mice has been debated
in numerous reports over time until now. Earlier reports
proposed a Th2 response (especially IL-4) (or a mixed Th1
and Th2 response) [1, 32–35] whereas recent evidences
demonstrated the importance of the Th1 response especially
IFN-γ (see [36–41] Figure 1), including IFN-γ inducible IL-
12 [42, 43]a n dI L - 1 8[ 44, 45]. Those are involved in the
onset and progression of the autoimmune disease in lupus.
Moreover, the current consensus is that IL-4 production is
notincreasedinSLEpatientsbycDNAassay[46].Onemight
suppose that the autoimmune manifestations of the SLEJournal of Biomedicine and Biotechnology 3
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Figure 2: Notion of IFN-α/β and TNF-α axis balance proposed by Banchereau and Pascual [26]. Environmental factors (e.g., viral
infections), apoptotic bodies and immune complexes stimulate pDCs through the coengagement of FcγR and TLRs trigger the production
of IFN-α/β from pDCs and following production of TNF-α occurs. Also IFN-α/β induces the generation of mature DCs. Banchereau and
Pascud hypothesize that increased production of TNF-α may weaken IFN-α/β production, leading to prevention of lupus. Also tolerogenic
peptide activates Treg cells leading to production of TGF-β may inhibit DCs activity, resulting in the suppression of lupus development [27].
These events suppress the lupus development, whereas immunogenic DCs suppress function of Treg cells. Thus Horwitz [22]p r o p o s e dT
reg regulation together with tolerogenic DCs for therapy. Important cytokines are shown in bold arrows letters.
are not based solely on a Th1 type autoimmune response,
since Th2 type cytokines such as IL-6, which promotes the
terminal diﬀerentiation from activated B cells to antibody
producing plasma cells, are apparently involved [11, 47].
In addition, proinﬂammatory cytokines (e.g., IL-1, TNF-α)
[12] are also involved other than Th1 and Th2 cytokines.
Shimizu et al. [48] reported the evidences that MRL/lpr
mice develop diﬀuse proliferative glomerulonephritis similar
to that in human lupus nephritis (WHO class IV) was
associated with autoimmune responses dominated by IFN-γ,
whereas MRL/lpr mice lacking WSX-1 gene, which encodes
a subunit of the IL-27R with homology to IL-12R, developed
disease resembling human membranous glomerulonephritis
(WHO class V) with a predominance of IgG1 in glomerular
deposits, accompanied by increased IgG1 and IgE in the sera.
Furthermore, late stages of murine lupus characterized
by renal ﬁbrosis (glomerulosclerosis) have been considered a
Th2-mediated disease [49].
In fact, many immune responses do not reﬂect an
absolute Th1 or Th2 pattern as described above, but func-
tionally dominated by either Th1 (especially IFN-γ)o rT h 2
(especially IL-4) cytokines in immune disease are pointed
out by Paul and Seder [50]. At present, there are general
agreementsthatinitiationofeventsintheearlyandfollowing
phases of nephritis is due to Th1- and Th1-related cytokines,
and therefore, an altered ratio of IFN-γ/IL-4 producing.
Th cell axis could determine the nature, strength, and
durationofsystemicautoimmuneresponsesinlupusnephri-
tis [1].
[2] IFN-γ Targeted Therapy
(1) Synthetic Oligodeoxynucleotides (ODN). It has been
reported that suppressive synthetic oligodeoxynucleotides
(ODN)containingTTAGGGmotifs,whicharefoundathigh
frequency in the telomeric region of mammalian chromo-
somes [52], can downregulate inﬂammatory responses that
are injurious to the host [53, 54]. Sano et al. [55]h a v e
reported ODN without CpG motifs, a 6-base DNA motif
consisting of an unmethylated CpG dinucleotide ﬂanked by
tow 5  purines and two 3  pyrimidines, work as adjuvant
for the induction of Th2 diﬀerentiation in a sequence-
independent manner [56].
Dong et al. [57] reported that synthetic ODN delay the
onset of glomerulonephritis and prolong survival in lupus-
prone B/WF1 mice, which is one of excellent mouse models
for human lupus (Figure 3) with a signiﬁcant reduction in
productions of anti-dsDNA autoantibody, IFN-γ, and IL-12.4 Journal of Biomedicine and Biotechnology
New Zealand black (NZB) mouse
H-2:d/d
• Autoimmune hemolytic anemia( IgG1 type)
• Production of Auto-antibodies from B1 cells
New Zealand White (NZW) mouse
H-2:z/z
• No autoimmunity
• B-cell chronic lymphocytic leukemia
NZB x NZW F1 (B/WF1)m o u s e
H-2:d/z
8w
32w
Lupus-like syndrome
1. Polyclonal B cell activation
2. Production of anti-nuclear antibodies
(ANA), anti-dsDNA and anti-gp70
3. Formation of immune complexes (ICs)
in the blood
4. ICs-mediated glomerulonephritis
5. Excretion of protein in urine
6. Overt disease (edema,
increase in BUN and blood creatinine)
7. Death
Aging
Peripheral
pattern
Homogenous
pattern
Figure 3: Female B/WF1 mice constitute one of the best-studied animal models of spontaneous systemic lupus erythematosus (SLE) in
human. Their characteristic features include polyclonal B-cell activation, production of autoantibodies against autoantigens (e.g., notably
dsDNA), which occur when the animals are 5-6 months of age, and development of glomerulonephritis with age which is the major cause
of death due to renal failure. Moreover, animals respond to cortisone similar to human patients with SLE [51]. H-2: mouse MHC. ANA:
antinuclear antibody.
In addition, production of proinﬂammatory cytokines, espe-
cially IL-6 was blocked by those treatments. Also, repeatedly
treated mice with suppressive ODN before or after the
onset of proteinuria signiﬁcantly prolonged lifespan with
delaying the onset and progression of glomerulonephritis
in B/WF1 mice. Clinical improvement was accompanied
by a signiﬁcant reduction in anti-dsDNA autoantibody
production and by signiﬁcantly reduced secretion of IFN-γ
and IL-12 in vivo. They monitored body weight and general
activity as measures of animal well-being by these general
criteria, suppressive ODN did not adversely impact animal
health (data not shown). They concluded that suppressive
ODN may be of beneﬁt in the treatment of chronic systemic
autoimmune diseases such as SLE.
Although, the mechanism by which suppressive ODN
block ongoing inﬂammatory immune responses is incom-
pletely understood, suppressive ODN may directly block the
signal transduction cascade associated with the production
ofIFN-γ andIL-12,therebyinﬂuencingtheTh1/Th2balance
in vivo [56]. In light of evidence that suppressive ODN
slows the development of organ-speciﬁc autoimmune Th1
diseases in autoimmune type 1 diabetes (T1D) animal
models, suggesting that these agents may be broadly useful
in the prevention and treatment of diseases characterized by
the overproduction of Th1 and/or inﬂammatory cytokines.
In this report, the sensitivity against pathogens and Th2-
dependent allergic diseases is unclear.
(2) Bioactive Th2 Cytokines (IL-4 and IL-10). Suppression
of IFN-γ by recombinant (r)IL-4 or rIL-10 may be eﬀective
to preventive lupus. However, a large dose and frequent
administrations of rIL-4 are necessary to maintain the
eﬀective concentration of IL-4 on prevention of T1D in
murine models [58, 59], since its half life is very short (t1/2
= 19 ± 2 min) in the circulation in mice administrated
intravenously by murine rIL-4 [60]. A large dose of rIL-4Journal of Biomedicine and Biotechnology 5
or rIL-10 (t1/2 = several hours) [61] as the use of Th1/Th2
balance shaft may evoke unexpected side eﬀects in recipients,
such as disturbance of host immune states due to temporal
large amounts. In addition, the therapy by use of those
bioactive cytokines is very expensive. Thus, at present, there
is no report using those in lupus model and human lupus.
(3) Anti-IL10 Antibody. Llorente et al. [8] showed ﬁrstly
in their pilot study that elimination of IL-10 (one of Th2
cytokines)bymurinemonoclonalantibody(mAb)tohuman
patients (20mg/day intravenous administration of an anti-
IL-10 murine mAb (B-N10) for 21 consecutive days) with
SLE led to a rapid decrease of disease, which was maintained
for 6 months of followup. The study indicates that the use
of IL-10 antagonists may be beneﬁcial in the management
of refractory SLE. They discussed that this study appears
encouraging to justify a larger, randomized, and blinded
study using a humanized anti-IL-10 mAb to determine
whether this approach allows reduction of corticosteroid
treatment including the determination of long-term control
of the disease by repeated administration of an anti-IL-10 in
patients with poorly controlled SLE.
IL-10, which is considered to be anti-inﬂammatory,
has properties that are somewhat ambivalent, since it can
stimulate the immune function of some cell populations
and is a potent anti-inﬂammatory cytokine with strong
inhibitory eﬀects on Th1 cells and inﬂammatory reactions
[62]. However, lupus patients with pulmonary involvement
have a higher proinﬂammatory cytokines proﬁle IL-6, IL-8,
IL-10, IL-12, IFN-γ,a n dT N F - α, suggesting the involvement
of IL-10 in many facets of development and prognosis of
SLE. If that is the case, anti-IL-10 antibody may contribute
to suppress lupus by the diﬀerent mechanisms other than the
concept of Th1/Th2 balance shift.
(4) IL-4 Transgene. To address the issue of whether IL-
4-induced immune deviation can provide protection from
ongoing lupus, Santiago et al. [63] reported protective eﬀect
on the development of lupus-like glomerulonephritis in
the (NZW × B6·Yaa)F1 murine model of SLE expressing
constitutively an IL-4 transgene (pEP-IL-4) by B cells [64],
since this would help establish new strategies for the
development of therapeutic approaches in SLE and related
human autoimmune diseases.
They showed protection that occurred in association
with marked changes in the IgG subclasses rather than in
total levels of anti-DNA autoantibodies, with an absence of
IgG3 and a decrease of IgG2a subclasses. This was accompa-
nied by a similar modulatory antibody response of the IgG
subclass antibody against T-cell-dependent antigen (heat-
aggregated human IgG: HGG), but not T-cell-independent
antigen (LPS: lipopolysaccharide). The decrease of IgG3
and IgG2a autoantibody production in the transgenic mice
is most likely due to the inhibitory eﬀect of IL-4 on the
development of the Th1 subset, suggesting downregulation
of Th1 autoimmune responses by IL-4, although they did
not show values of Th1 and Th2 cytokines. This approach
may be applicable as one of strategies for the therapeutic
approaches in SLE and related human autoimmune diseases.
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Figure 4: Survival rate among three groups. Mice were treated
intraperitoneally either with 100μg of the IL-4pDNA, 100μgo f
plasmid only or saline only at the age of 4, 6, 8, 12, 16, 20, 24,
28 and 32 weeks.
∗P <. 001 (comparison between the IL-4pDNA
group and two controls). Provided here is courtesy of NDT 2007,
22, 3131-8: Oxford University Press).
However, pEP-IL-4 transgenic mice are more susceptible to
Leishmania major infection than nontransgenic mice [65]i n
which Th1 cells play a crucial role in protection against L.
major infection [66]. Also, they pointed out that it will be
important to determine whether IL-4 transgene expression
also leads to protection against SLE in other murine models
such as B/WF1 and MRL-lpr/lpr mice, in terms of the issue
of whether IL-4-induced immune deviation can provide
protection from ongoing disease [67].
(5) IL-4-Expressing Plasmid DNA. We have reported that
preventive eﬀects of IL-4-expressing plasmid DNA (pIL-4)
using the plasmid vector PCGGS (kindly supplied by Dr.
Miyazaki), on lupus development in lupus-prone female
B/WF1 mice [68]. IL-10-expressing DNA plasmid, which
prevent T1D in model mouse [69], was not used, because
as described in section [I]-(3), the use of it seems to be
complicated in lupus. Successful prevention of pIL-4 in
T1D experimental animal model [58, 70]e n c o u r a g e su s
for application to lupus. B/WF1 mice monthly injected
repeatedly with the IL-4p DNA intraperitoneally before and
after the active phase drastically delayed the development
of glomerulonephritis with deposits of IgG2a and C3
leading to excretion of urine protein, and they showed
prolonged survival (Figure 4). Clinical improvement was
associated with the reduction in productions of IgG anti-
dsDNA autoantibodies with reduction of IFN-γ production
and slightly increased IL-4 production from splenic cell,
suggesting IL-4pDNA administration may delay lupus onset6 Journal of Biomedicine and Biotechnology
and progress by shifting from Th1 to Th2 responses. In
addition, CRFK cell line transfected with the IL-4pDNA
produced enough concentration of IL-4 (approximately
200pg/mL) more than 8 days in vitro. Thus, compared to
the administration of the bioactive recombinant IL-4, IL-
4pDNA may be advantageous and useful for the reduction
of Th1-dependent autoimmunediseases including lupus.On
the other hand, the plasmid accelerated, to some extent,
the lupus development compared to the nontreated control
group. It seems likely, since B/WF1 mice administrated with
plasmid containing many CpG motifs [71], which promote
lupus [47], may interact and stimulate a variety of immune
cells, and then those cells may secrete mainly Th1 (IFN-γ)
and Th1-related cytokines (IL-12 and IL-18) including IL-
6[ 72, 73]. However, values of IL-4 produced by IL-4pDNA
may be higher than those of IFN-γ production by CpG
ODN stimulation. As a result, IFN-γ production may be
inhibited by mutual inhibitory eﬀects of Th1/Th2 cytokines
[28]. In addition, CpG ODN may have a possibility to
produce anti-DNA antibody formation [73]. However, this
possibility may be negligible, since anti-dsDNA production
in the IL-4pDNA-treated mice was reduced. Moreover,
long-time survived mice did not show any clinical signs
s u c ha sad u l lm o v e m e n ta n dal o s so fh a i rg l i t t e r i n g
by renal failure, supporting that idea. Also, there was no
development of systemic Th2 response by this treatment
like alum adjuvant (aluminium hydroxide gel), which itself
induces strong systemic Th2 response (unpublished data).
In this experiment which cell type takes up the IL-4pDNA
after injection intraperitoneally is unknown. Thus, further
study is needed to clarify cell types, including eﬃciency of
transfection,whichcellstakeuptheIL-4pDNAandhowlong
theexpressionoftheIL-4pDNAlasts,includinghowsecreted
IL-4 protein aﬀects IL-4 receptor since the IL-4α receptor-
chain is a component of both the IL-4 and the IL-13 receptor
[20].
Mazda [74] have reported that nonviral gene transfer
technologies include naked DNA administration, electrical
or particle-mediated transfer of naked DNA such as low
immunogenicity, inexpensiveness, and ease in handling, but
the common disadvantage is the transfection eﬃciency. It
remains to be determined whether an optimal dose of pIL-
4w i l lh a v eb e n e ﬁ c i a le ﬀects on autoreactive T and B cells
without compromising immunity to foreign antigens.
(6) IL-5 Transgene. IL-5 preferentially activates B1 cells to
produce natural antibodies cross-reactive to self antigens
[75]. Wen et al. [76] have reported that B/WF1 mice
congenic for IL-5 transgene (TG-F1) reduced the incidence
of lupus nephritis with decreased anti-DNA antibodies
and those produced by splenic B cells in vitro. As TG-F1
mice aged, frequencies of peripheral B1 cells progressively
increased, and the mice frequently developed B-cell chronic
lymphocytic leukemia (B-CLL). They suggest that dysreg-
ulated, continuous high expression of IL-5 in SLE-prone
mice may directly or indirectly mediate a skewed signaling
of proliferation/diﬀerentiation of self-antigen-activated B1
cells, leading to suppression of autoimmune disease, but
instead to aberrant expansion of B1 cells, giving rise to
B-CLL. Down regulation of Th1 cytokines in IL-5 transgenic
mice is unclear.
(7) IL-12-Expressing Plasmid DNA. Hagiwara et al. [77]
have reported the therapeutic eﬀects of IL-12-encoding
plasmid, depending on the concept that lupu is Th2 dis-
ease. Thus, they aimed paradigm shift from Th2 to Th1
polarized immune reaction for lupus therapy. MRL/MP-
lpr/lpr mice were treated with IL-12-encoding plasmid DNA
intramuscularly (every 4 weeks, starting at 4 weeks of age).
This intervention signiﬁcantly inhibited the accumulation
of CD4(−)CD8(−)d o u b l en e g a t i v eTc e l l sr e d u c i n gl y m -
phadenopathy and splenomegaly. A signiﬁcant decrease in
serum IgG anti-DNA autoantibody titers with a reduction
in the proteinuria and glomerulonephritis. However, serum
IFN-γ level was increased. They suggested that the cytokine
balance was skewed towards Th1. However, they discussed
the mechanism by this therapy is not totally dependent on
an IFN-γ-mediated pathway. It may be that this plasmid also
induced the production of regulatory cytokines that counter
balanced inﬂammatory cytokines [78].
[2] Elimination (Neutralization) of Th1 and
Th1-Related Cyokines
(1) IFN-γ R/Fc-Expressing Plasmid DNA. Ozmen et al. [79]
have reported that mouse soluble IFN-γ receptor (IFN-γ R)
prevented the onset of glomerulonephritis in B/WF1 mice.
Lawson et al. [80] have attempted to eliminate (neu-
tralize) IFN-γ in mouse lupus models using soluble recom-
binant IFN-γ R. Intramuscular injections of plasmids with
cDNA encoding IFN-γ R/Fc can retard lupus development
and progression in MRL-Fas(lpr) mice even though when
this treatment was initiated at advanced stage. Theraphy
signiﬁcantly reduced serum levels of IFN-γ as well as
disease manifestations (autoantibodies, lymphoid hyperpla-
sia, glomerulonephritis, and mortality), when treatment
was initiated at the predisease stage. On the other hand,
there were no changes in mRNA expression levels from
splenic cells for IFN-γ, IL-2, IL-4, IL-10, IL-12, and TNF-
α with the exception of twofold increase. This therapy
makes application of this nonviral gene therapy in humans
with lupus and perhaps other autoimmune/inﬂammatory
conditions, since this method seems to be nontoxic and safe
with long-term expression. They postulated that a major
eﬀect of IFN-γ blockade would be due to downregulation
of MHC expression, although it is very diﬃcult to deﬁne
the exact mechanism(s) by which this cytokine, which has
highly pleiotropic properties, promotes autoimmunity. In
addition to elimination inﬂammatory cytokines such as IL-
1a n dT N F - α other than IFN-γ [80], administration of
cDNA encoding soluble TNF-α receptors, or IL-1 receptor
antagonist (IL-1ra), protects against lupus [12, 81].
(2) IL-18 cDNA Vaccination. Boss` u et al. [82]h a v er e p o r t e d
protective eﬀects of IL-18 cDNA vaccination on lupus.
Their idea elicited a speciﬁc anti-IL-18 antibody response
by reducing the activity of endogenous IL-18, which is
an inducer of IFN-γ in T lymphocytes and NK cells, inJournal of Biomedicine and Biotechnology 7
MRL/Mp-Tnfrsf6lpr (lpr) mice closely resembling human
SLE. Young lpr mice were vaccinated against autologous IL-
18 by repeated intramuscular injection of a cDNA coding
for the murine IL-18 precursor. Vaccinated mice produced
autoantibodies in sera to murine IL-18, and they exhibited
a signiﬁcant reduction in spontaneous lymphoproliferation
and IFN-γ production as well as less glomerulonephritis and
renal damage. Moreover, mortality was signiﬁcantly delayed
in anti-IL-18-vaccinated mice. These studies support the
notionthatIL-18playsamajorroleinthepathogenesisofthe
autoimmune syndrome of lpr mice and that a reduction in
IL-18 activity could be a therapeutic strategy in autoimmune
diseases.
However, the exact role of the IL-18 cDNA vaccination in
prevention is unclear.
(3) IL-12- and IL-18-Encoding Plasmids. Given the facts
that injection of recombinant IL-12 or IL-18 proteins in
lpr mice worsened the lupus-like disease [83, 84], and
elevated IL-12 and IL-18 serum levels were found in SLE
patients [85, 86]. Neumann et al. [87] have reported that
MRL/Mp-Tnfrsf6(lpr) (lpr) mice with increase in both TNF-
α and IFN-γ serum concentrations in age, model for human
SLE, were injected intramascularly with plasmids encoding
IL-12 and IL-18, either alone or in combination. Five
biweekly injections of combined plasmids starting at 4-5
weeks of age diminished serum levels of TNF-α and reduced
an ability of lymphocytes from treated mice to produce
IFN-γ in vitro. Injection of both plasmids synergistically
attenuated the development of autoimmune syndromes,
lymphoproliferationinsecondarylymphoidorgans,protein-
uria and kidney damage, and pneumonitis. Also, IL-12/IL-
18 cDNA treatment reduced serum TNF-α concentrations.
The constitutively enhanced serum TNF-α level in lpr mice
decreased more eﬃciently by the injection of both cDNAs
encoding IL-12 and IL-18 when compared with the single
injection.
Lymph node cells from IL-12/IL-18-treated mice pro-
duced less IFN-γ after in vitro stimulation, and IL-12/IL-
18 cDNA treatment does not aﬀect anti-dsDNA IgG levels.
Regarding the possibly reduced IFN-γ generation, the alter-
ations might be due to either the speciﬁc elimination of IFN-
γ producing T lymphocytes or NK cells from the whole-cell
population, or due to their reduced capability to produce
IFN-γ, if they persist.
They discussed the cDNA injection procedure presum-
ably inducing anti-IL-12 and anti-IL-18 activities although
direct evidences are not obtained. They concluded that IL-12
and IL-18 synergistically aﬀect the pathogenesis of the Th1-
dependent autoimmune syndrome of lpr mice and that both
IL-12andIL-18maybeatherapeuticoptioninthetreatment
of autoimmune SLE.
[3] Suppression of Th1, Th2, and
Other Immunocompetent Cells
(1) TGF-β-Expressing Plasmid DNA or IL-2-Expressing Plas-
mid DNA. The therapy focusing on wide suppression of
immunocompetent cell has been reported by Raz et al.
[88]. MRL/lpr/lpr mice monthly injected intramuscularly
with plasmids cDNA expression vectors encoding for TGFβ
or IL-2. Injections (between 6 and 26 weeks) signiﬁcantly
elevatedthe serum levels of TGF-β and IL-2 compared with a
controlplasmidwithoutinsert.TGF-β encodingplasmidhad
beneﬁcial eﬀects in murine SLE with a prolonged survival of
70% at 26 weeks compared with 40% in the control group,
decreased antichromatin and rheumatoid factor antibodies
and a 50% decrease in total IgG production. Renal function
was improved with reduced blood urine nitrogen (BUN)
levels and kidney inﬂammation. Those beneﬁcial eﬀects
occurred in apparent absence of local or systemic side eﬀects.
These eﬀects by TGF-β-expressing plasmid DNA may be
due to suppressed function of CD4(Th1,Th2), CD8 T,B and
macrophages. In contrast, IL-2 cDNA injections appeared
harmful with a decreased survival to 20% at 26 weeks
( s u r v i v a lr a t eo fn o n t r e a t e dc o n t r o lm i c e :4 0%a t2 6w e e k s ) ,
enhanced total IgG synthesis and autoantibodies production
with 4.5-fold increase in antichromatin antibodies. They
concluded that somatic gene therapy may provide simple,
inexpensive and eﬀective therapies for the long-term control
of autoimmune diseases by TGF-β-expressing plasmid DNA.
Huggins et al. [89] also investigated the eﬀects of IL-
2a n dT G F - β gene therapy in MRL lpr/lpr mice with a
diﬀerent approach. The mice were treated orally with a
nonpathogenic strain of Salmonella typhimirium bearing
the aroA-aroD-mutations and carrying the murine genes
encoding IL-2 and TGF-β.T G F - β gene therapy produced
no improvement in pathology and generally had opposite
eﬀects to those of IL-2. IL-2 gene therapy restored the
defective T-lymphocyte proliferative response to mitogen
and suppressed the autoantibody response, nephritis, and
growth of lymphoid tumours.
The reasons of these diﬀerences are unclear. Mageed
and Prud’homme [78] suggested that it is unclear to what
extent the cytokines enter lymphoid tissues and/or the
circulation, and how immunological eﬀects are mediated.
Therefore, these results must be interpreted with caution,
and are diﬃcult to compare with those obtained by other
methods of delivery. Thus, they claimed these contradictory
results highlight the risks inherency in using cytokines as
therapeutic molecules.
[4] Normalization of T Cell Population
(1) IL-2/Vaccinia Recombinant Virus. Gutierrez-Ramos et al.
[90] tried lupus therapy in MRL/lpr mice by altering abnor-
mal T-cell population to normal T-cell population, since the
intrinsicabnormalityofTcellsinthismousestrain(defectin
IL-2 production appears at 4–6 weeks of age in MRL lpr/lpr
and BXSB mice, and somewhat later in the B/WF1 mouse
and becomes more pronounced with disease progression
[78]. Mice-vaccinated intraperitoneally with live vaccinia
recombinantvirusesexpressingthehumanIL-2geneshowed
prolonged survival, decreased autoantibody production and
rheumatoidfactortitres,markedattenuationofkidneyinter-
stitial inﬁltration and intraglomerular proliferation, as well
as clearance of synovial mononuclear inﬁltrates. Inoculation
with the IL-2/vaccinia recombinant virus led, additionally, to8 Journal of Biomedicine and Biotechnology
drastic reduction of the CD3+ CD4−CD8− double-negative
T-cell population, and improved thymic diﬀerentiation and
restoration of normal values of mature cells in peripheral
lymphoid organs.
In contrast, IL-2 treatment enhanced the disease as
described in section [3]-(1). These opposite data suggest
multifunction of IL-2 in vivo or methodological diﬀerence
including disease process.
[5] Costimulation Blockade
(1) Anti-CD154 (CD40L) Therapy. Wang et al. [91]d e t e r -
mined the immunologic eﬀects of anti-CD154 (CD40L)
therapy in the B/WF1 mouse (20-week-old and 26-week-
old) treated with continuous hamster anti-CD154 intraperi-
toneally biweekly for 6 months. IgG anti-dsDNA antibodies
decreased during therapy and disease onset was delayed, but
immune tolerance did not occur. During treatment, there
was marked depletion of CD19+ cells in the spleen; however,
autoreactive IgM-producing B cells could still be detected. In
contrast,fewIgGanti-dsDNA-secretingBcellsweredetected.
Eightweeksaftertreatmentcessation,thefrequencyofBcells
producing IgG anti-dsDNA antibodies was still decreased in
50%ofthemice,andactivationandtransitionofTcellsfrom
the naive to the memory compartment were blocked. Anti-
CD154 treatment blocked both class switching and somatic
mutation by using the marker gene VHBW-16 and induced
a variable period of relative unresponsiveness of IgG anti-
dsDNA-producing B cells, as shown by decreased expression
of the CD69 marker and failure to generate spontaneous IgG
anti-dsDNA-producing hybridomas. Treated mice mounted
an attenuated IgM response to the hapten oxazolone and
produced no IgG antioxazolone antibodies.
Anti-CD154 is a B-cell depleting therapy that aﬀects
multiple B-cell subsets. Activation of both B and T cells
is prevented during therapy. After treatment cessation,
autoreactive B cells progress through a series of activa-
tion steps before they become fully competent antibody-
producing cells. Wang et al. have stressed that the general
immunosuppression induced during treatment will need to
be taken into account when using B-cell depleting regimens
in humans.
(2) Adenovirus Vector Expressing CTLA-4/IgG. Takiguchi
et al. [92] reported that gene therapy strategy is to
prevent the eﬀector T-cell function by blocking costim-
ulation, because involving Th1 and Th2 cytokines in
lupus pathogenesis suggests the diﬃculty to target speciﬁc
cytokines. They demonstrated protective eﬀects of aden-
ovirus vector containing CTLA4IgG, which binds to B7
molecules and inhibits B-cell diﬀerentiation to plasma cells,
gene (Adex1CACTLA4IgG:AdCTLA4IgG) delivery on the
development of lupus nephritis, in MRL/lpr mice. It was
demonstrated that a single administration of intravenous
injection of AdCTLA4IgG into MRL/lpr mice resulted in
almost complete amelioration of lupus nephritis. However,
side eﬀects such as increased susceptibility to pathogen due
to reduced general immune reaction by this treatment are
unclear.
Mihara et al. [93] also reported that Ad-CTLA4Ig, which
blocks the B7/CD28 pathway, prevents the onset of disease
in B/WF1 mice treated at the age of 20–22 weeks with a
single intravenous injection of high dose (2 × 109 pfu). This
eﬀect is associated with decreased expansion of both the
IgM and IgG autoreactive B-cell population, inhibition of
immunoglobulin class switching, and a marked decrease in
the numbers of activated CD4+ T cells. In contrast, intrinsic
B-cell hyperreactivity and the survival of plasma cells in the
b o n em a r r o w ,b o t ho fw h i c ha r el e s sd e p e n d e n to nT - c e l l
help, appear to be unaﬀected by CTLA4Ig. Administrated
Ad-CTLA4Ig existed in the serum for a long time and an
immune response to the adenoviral vector was absent. More
importantly they showed that CTLA4Ig did not induce a
permanent state of tolerance in B/WF1 mice.
(3) (AAV8)-CTLA-4/Ig and AAV8-CD40/Ig. Ye et al. [94]
investigated the potency of costimulatory blockade with
adeno-associated virus- (AAV)-mediated gene transfer in
prevention and reversal of lupus in a murine model. AAV
vectors expressing CTLA-4Ig or CD40Ig were injected into
intraperitoneally NZB/NZW mice. A single injection of
AAV serotype 8 (AAV8)-CTLA-4Ig in neonatal B/WF1 mice
before the onset of lupus eﬀectively delayed and inhibited
autoantibody production, proteinuria, and kidney damage
and prolonged their lifespan. In addition, coinjection of
AAV8-CTLA-4Ig and AAV8-CD40Ig vectors into neonatal
mice achieved the synergistic eﬀect and the best eﬃcacy.
The preventive eﬀects were attributed to the suppression
of CD4+ T-cell activation and the transition from naive
to memory T cells. Moreover, coinjection of these 2 vec-
tors in adult mice reversed existing autoantibody levels,
suppressed the development of proteinuria, and prolonged
their lifespan. The therapeutic eﬀects were found to be
dependent on the vector dose. Moreover, long-term, high-
level costimulatory blockade transgene expression does not
completely suppress the host humoral immune response to
KLH, a T-cell-dependent antigen. AAV-mediated long-term
gene expression did not severely suppress the host humoral
response to foreign antigen. They showed that delivery of
costimulatory inhibitor transgenes by AAV vectors could
prevent and reverse lupus in this murine model, suggesting
the potential of AAV-mediated gene transfer as an alternative
treatment for lupus, since it did not completely suppress the
host humoral response to foreign antigens.
(4) Adenovirus Vector Expressing PD-L1 Gene with Anti-B7h
mAb. Deliberate delivering of negative costimulation to halt
unwanted T- and B-cell activation has been tested by Ding
et al. [95], although blocking positive T-cell costimulation
has shown eﬀectiveness in preventing the onset of murine
lupus as shown in sections [5]-(1) and [5]-(2). They focused
on enhancing PD-1 signaling because unlike CTLA-4, PD-
1 is more broadly induced on not only T, but also B and
myeloid cells after activation [96]. PD-L1 (also called B7-
H1) is one of the ligands of this novel immunoinhibitory
receptor [97]. Engaging PD-1 by PD-L1 could inhibit the
activation of both T and B cells [98, 99]. They constructed
an adenovirus containing the full-length mouse PD-L1 geneJournal of Biomedicine and Biotechnology 9
(Ad.PD-L1), and tested its eﬃcacy alone and together with
an anti-B7h (inducible costimulator ligand, B7 homologous
protein (B7h) called as ICOS-L [100]) mAb to block ICOS, a
new member of the CD28 family of costimulatory molecules
that is induced on T cells after activation, and regulates
T-cell-dependent humoral immune responses [101, 102],
in preventing lupus nephritis in BXSB mice, which spon-
taneously develop an autoimmune syndrome characterized
byhypergammaglobulinemia,autoantibodyproduction,and
development of fatal glomerulonephritis that closely resem-
bles SLE in humans. This combined therapy in mice with
intravenous injection dramatically delayed the onset of pro-
teinuria, eﬀectively inhibited IgG autoantibody production,
and signiﬁcantly reduced hypercellularity and deposition of
IgG in glomeruli, resulting in almost complete amelioration
of lupus nephritis in these animals. Their results indicate the
therapeutic potential of simultaneous stimulation of PD-1-
mediated pathway and blockade of ICOS-B7h costimulation
in the prevention of human lupus nephritis, suggesting the
beneﬁts of shifting the balance of positive versus negative
costimulation on eﬀector T cells in ongoing autoimmune
diseases.
[6] Blys Blockade
(1) Adenovirus Vector Expressing Transmembrane Activator
and CAML Interactor Receptor (TACI). Liu et al. [103]
examined the eﬀect of BLyS blockade in 3 animal models
of lupus depending on the evidences that serum BLyS
(also known as TALL-1, THANK, zTNF4, and BAFF) is
increased in autoimmune diseases, both in animal models
and in humans. Antibodies and lupus-like disease mani-
festations were examined in mice after administration of
a single intravenous injection of an adenoviral construct
for transmembrane activator and CAML interactor receptor
(AdTACI) that produces high serum levels of TACI-Fc fusion
protein. In C57BL/6 (B6) lpr/lpr mice (B6.lpr/lpr), which
were used to model of autoimmunity in absence of severe
disease, treatment of younger mice with AdTACI prevented
the development of hypergammaglobulinemia. In contrast,
use of AdTACI for BLyS blockade had only transient eﬀects
on the levels of IgG in normal B6 mice. AdTACI blocked
the development of autoantibodies in younger B6.lpr/lpr
mice and reversed the production of autoantibodies in
older B6.lpr/lpr mice, and also reduced the numbers of
splenic plasma cells. In MRL.lpr/lpr mice, which were used
to examine disease manifestations, AdTACI reduced the
extent of glomerulonephritis and proteinuria and improved
survival, but had little eﬀect on T-cell inﬁltration and
interstitial nephritis. However, in BW/F1 mice, AdTACI
induced neutralizing anti-TACI antibodies and failed to
reduce the numbers of B cells. BLyS blockade has little eﬀect
on IgG levels in normal mice, but reverses the production
of spontaneously produced IgM and IgG autoantibodies
in setting of established autoimmunity. Blockade of BLyS
ameliorates B-cell-dependent disease manifestations even in
the MRL.lpr/lpr model, but its eﬀectiveness on autonomous
T-cell aspects of the disease is limited. Moreover, its eﬀective-
nessisneutralizedbyanti-TACIantibodieswhenitispresent.
These results provide a basis for understanding the potential
eﬀects of BLyS blockade in human disease.
[7] Suppression of Nephritic Kidney Inﬂammation
(1) Adenovirus Vector Expressing Tβ-ExR. Haviv et al. [104]
have reported that systemic adenoviral (Ad) gene ther-
apy for renal disorder in the context of blocking renal
ﬁbrosis by AdTbeta-ExR, which encodes a chimeric sol-
uble molecule comprising the entire ectodomain of the
h u m a nt y p eI IT G F - β receptor, genetically fused to the Fc
fragment of the human IgG1 (sTbetaRII), and AdCATβ-
TR, which encodes only the dominant-negative truncated
ectodomain of the human type II TGF-β receptor, intramus-
cularly in MRL/MpJTnfrsf6lpr mice, which are homozygous
for the FAS-protein receptor (lpr, lymphoproliferation)
spontaneous mutation (Tnfrsf6lpr) and develop systemic
autoimmunity and ICs-mediated glomerulonephritis. This
therapy focussed on suppression of kidney inﬂammation
using recombinant adenoviral (Ad) vectors holding many
advantages, such as infection of a wide range of quiescent
renal cells and the potential for organ targeting employing
genetic or antibody conjugation strategies TGF type II
receptor (AdT-ExR) to block TGF-β, a cytokine playing a key
role in ﬁbroproliferative renal disorders and TGF-β,i sak e y
regulator of production, degradation, and accumulation of
extracellular matrix.
The onset of the autoimmune disease is at about 8 weeks
of age and females die earlier than males, thereby resembling
systemic lupus erythematosus-like autoimmune syndromes.
sTbetaRII was detected in the glomeruli after remote i.m.
injection of AdTbeta-ExR, but not the control AdCATβ-
TR, indicating renal deposition of the heterologous soluble
fusionproteinafteritsexpressioninthemuscleandsecretion
into the circulation. AdTbeta-ExR, but not AdCATbeta-TR,
could transiently inhibit mesangial expansion, glomerular
hypercellularity, proteinuria, and cortical interstitial ﬁbro-
sis. However, amelioration of renal disease in CXCR3−/−
MRL/lpr mice therefore seems to be more a result of an
impaired cellular immune response, rather than an impaired
humoral immune response.
[II] Balance Shift from Immunogenic to Tolerogenic Dendritic
Cells (DCs)
[1] Immunogenic DCs Determine Lupus. It is well known
that viral infections, in general, trigger unabated production
of IFN-α/β. SLE patients have long been known to display
elevated levels of type I interferon (IFNα/β) in their serum
[105], but there are a few attention on the role of IFNα/β
compared to other cytokines in lupus pathogenesis. Pascual
et al. [105] proposed in 2001 that an excess IFNα/β might
break peripheral tolerance through the activation of myeloid
dendritic cells (mDCs). And since then, accumulating evi-
dences suggest causal roles of IFNα/β pathway (i.e., human
plasma cell diﬀerentiation and activation of CD8 T cells) in
human SLE.
It has also become evident that antigen–antibody com-
plexes (ICs) containing RNA and DNA activate DCs and B10 Journal of Biomedicine and Biotechnology
cells through interaction with FcγR and Toll-like receptor
(TLRs) 7, 8, and 9, respectively [85]. Thus, lupus-speciﬁc
autoantigens might act as TLR ligands and contribute to
IFNα/β and autoantibody production.
Horwitz [106] proposed in his review that an important
goal in the management of human SLE is to restore the
DCs together with regulatory T(Treg) cells [107], since
once the DC balance has been shifted back to tolerogenic
predominance, further stimulation of these tolerogenic DCs
with peptide autoantigens should expand or induce new
inducible (i)Tregs.
(1) Restoration of DCs and IFNα/β. There are two main
DC diﬀerentiation pathways [108]: mDCs and plasmacytoid
DCs (pDCs) [109]. Resident mDCs that encounter bacteria
at mucosal surfaces or at sites of tissue damage migrate
to the lymph node via aﬀerent lymphatics. Importantly,
mDC express receptors, such as TLRs, nucleotide binding
oligomerization domain (NOD) proteins, and lectins, to
capture these pathogens. Mouse mDCs express TLR7 and
TLR9 whereas human mDCs lack TLR7, but express TLR7
uponexposuretoIFN-α/β [110].mDCscanalsobeactivated
by immune complexes (ICs) through activating FcγRIIa
[111, 112].
Pascual et al. [105] have reviewed that increased IFN-
α/β induces the activation of immature mDCs that control
peripheral tolerance by deleting autoreactive lymphocytes.
IFN-α/β secreted from matured DCs activate and expand
autoreactive T cells, both helping autoreactive B-cell devel-
opment directly, and IFN-α/β also indirectly allows the
expansion and survival of CD4+ and CD8+ Tc e l l sa s
well as the diﬀerentiation of B cells into plasma cells.
Additionally the capture of apoptotic cells by mDCs and
nucleic acid-containing ICs by pDCs and autoreactive B
cells broadens the autoimmune reaction, thereby leading to
disease manifestations.
pDCs circulate in the blood and lymphoid organs
and by viral infection, these cells secrete large amounts
of IFN-α/β as well as other cytokines [109]. They also
diﬀerentiate into cells with DC morphology and function
[113]. Both mouse and human pDCs express TLR7 and
TLR9 and chromatin-containing and snRNPs-containing
ICs are internalized by pDCs via FcγRIIa and reach the
endosomalcompartmentwheretheyactivateTLR7andTLR,
respectively, leading to secretion of cytokines such as IFN-
α/β [26]. (The classic lupus autoantigens snRNPs can also be
directly internalized within endosomes where they stimulate
TLR7 and TLR8 [114].) Banchereau and Pascual [26]h a v e
demonstrated that ICs are formed when autoantibodies
are engaged with either (1) chromatin whose DNA can
interact with TLR9 inside pDC and B-cell endosomes or
(2) ribonucleoproteins whose RNA can interact with TLR7
also inside pDC and B-cell endosomes. TLR signaling in
pDC results in the secretion of IFN-α/β and IL-6. The
combinedtriggeringoftheautoreactiveBCRandTLRresults
in autoreactive B cell proliferation, and IFN-α/β induces
their diﬀerentiation into plasmablasts, and IL6 induces
their diﬀerentiation into autoantibody-secreting plasma
cells.
Mathian et al. [9] conﬁrmed the critical role of IFN-
α/β in SLE pathogenesis. In vivo delivery of IFN-α/β to
preautoimmune B/WF1 mice rapidly results in severe SLE.
dsDNA antibodies appear as early as 10 days after initiation
of IFN-α treatment, demonstrating a critical role for IFN-
α in the selection and expansion of autoreactive clones.
Proteinuria and glomerulonephritis-induced death occurred
inalltreatedmiceat9and18weeks,respectively,atimewhen
untreated mice did not show any sign of disease. Banchereau
and Pascual [26] reported that the cytokines yield distinct
DC subsets that might lead to distinct immunopathologies.
Immature DCs exposed to IFN-α/β or TNF-α will yield
distinct DC subsets that will uniquely polarize naive T cells
through the expression of diﬀerent cytokines and costimula-
tory molecules. They proposed the new concept that mutual
inhibitory eﬀects of TNF-α/IFN-α/β, which determine the
direction of diseases like the mutual inhibitory eﬀects of
Th1/Th2, which is proposed by concept of Monneaux and
Muller [5]. For example, excess TNF-α production from
immature DCs inhibits IFN-α/β production from immature
DCs, leading to inhibition of the development of lupus. On
the other hand, IFN-α/β polalized immunity lead to lupus,
by suppressing the production of TNF-α.
(2) Prevention by TNF. Gill et al. [115] found high amounts
of soluble TNF-α receptors and IFN-α/β found in SLE
patients. Jacob and McDevit [116] observed that soluble
bioactive TNF-α prevent lupus in B/WF1 mice, which bear
a genetic deﬁciency in TNF-α. These evidences suggest
that TNF-mediated downregulation of the IFN-α/β pathway
in therapy. However, the application of TNF-α remains
unclear, since TNF-mediated downregulation of the IFN-α/β
pathway is largely unknown.
[2] Treg Cells and DCs
(1) Regulatory T(Treg) Cells. Horwitz [106]p r o p o s e di nh i s
review that restoration of the balance between immunogenic
and tolerogenic DCs with correction of Treg numbers and
function is an important goal in the management of human
SLE, although still unsolved issues remain.
Toubi [117] reported that CD4+CD25+ Treg cells play
a role in autoimmune diseases in human. Restoration of
regulatory T(Treg) cell numbers and functions in individuals
with SLE has the potential to lead to remission of SLE by
shiftingbacktotolerogenicpredominanceinvivo[106].This
new strategy to normalize Treg function is expected to be
ideal therapy not only in SLE but also other autoimmune
disease including allergic diseases, which are typical Th2
diseases, although it is not conclusive [118]. Depletion
of CD4+CD25+ cells in B/WF1 hybrid mice accelerated
the onset of glomerulonephritis [119] and sialoadenitis
[120].
CD4+CD25+ natural or thymus-derived
CD4+CD25+Foxp3+ cells are decreased in young B/WF1
and/or SNF1 mice before they develop glomerulonephritis
and adoptive transfer of CD4+CD25+ cells from young
lupus-prone mice have some protective eﬀects on the
development of the disease [121].Journal of Biomedicine and Biotechnology 11
However, the evidence that Treg defects play a major
role in the perpetuation of this disease is only suggestive
in human [106]. Also, regulatory/suppressor T cells (Tregs)
consisted of heterogeneous populations of CD4 cells, CD8
cells, and even natural killer T cells [122], and approximately
5% of CD4+ cells in the mouse are Tregs that express Foxp3,
whereas only 1%-2% of the total CD4+ T-cell population
of CD4+ cells express Foxp3 in humans [106, 123]. Thus
Horwitz [106] pointed out that the cytokine and gene
expressionproﬁleofFoxp3+ TregsinSLEincomparisonwith
healthy subjects has yet to be deﬁned. Also, studies of Tregs
inSLEaremostlylimited toblood lymphocytesandthereare
controversy evidences that decrease in CD4+CD25 high cells
in some reports whereas there are no decrease in those cells.
Moreover, IL-2 and TGF-β can convert na¨ ıve
CD4+CD25− Tc e l l st oC D 2 5 +Foxp3+ suppressor cells
in mice, and Tregs-induced ex vivo with IL-2 and TGF-β
have protective lupus-like syndromes in mice [22, 124], but
similar conversion in humans is more complex and another
problem with measurements of Tregs in humans is that the
numbers circulating in the blood may not correlate with
the numbers and function of these cells in the tissues, and
there is very limited information concerning Foxp3+ Treg
numbers in lymphoid organs and in tissues of patients with
SLE [106].
In both mice and humans, CD4+CD25+Foxp3+ Tc e l l s
(iTreg) themselves diﬀerentiate into Th17 cells in the pres-
ence of IL-6 (and in the absence of exogenous TGF-β),
indicating that CD4+CD25+Foxp3+ regulatory T cells can
function as inducers of Th17 cells and can diﬀerentiate
into Th17 cells in both mice and human [125, 126]. Zheng
et al. [124] found that IL-2 and TGF-β downregulate IL-
6 receptor expression and IL-6 signaling. The resistance of
iTregs to Th17 conversion suggests that they can function
more eﬀectively than nTregs in the central role of IL-
2 in combination with TGF-β to maintain immunologic
homeostasis in autoimmune diseases [127]. However, this
has yet to be demonstrated in human [106]. Moreover,
the principal target of Treg activity is probably antigen-
presenting DCs rather than T cells [128, 129]. In addition,
Tregs may have direct suppressive eﬀects on B cells [130],
on natural killer cells [131] in mice. The contact-dependent
mechanism of action of CD4+Foxp3+ Tregs also remains
poorly understood [31].
(2) Interactions between Tolerogenic DCs and Treg Cells.
Min et al. [132] demonstrated that besides controlling the
activity of other T cells and B cells, evidence has been
obtainedthatTregsalsoinducetolerogenicDCsintransplant
tolerance in the C57BL/6 > BALB/c cardiac allograft model
using simultaneously targeting T cell and DC function using
anti-CD45RB mAB (CD45 is a single chain glycoprotein
expressed on hemopoietic cells such as T cells, and members
oftheCD45familyoftransmembraneproteintyrosinephos-
phatases are critically involved in lymphocyte activation.)
and LF 15-0195, a novel analog of the antirejection drug
15-deoxyspergualin, respectively. Moteober, LF inhibits DC
and anti-CD45RB mAb inhibits T-cell responses in vitro.
They concluded that tolerance induction is associated with
a self-maintaining regulatory loop in which tolerogenic DCs
inducethegenerationofTregcellsfromnaiveTcellsandTreg
cells programs the generation of tolerogenic DCs from DCs
progenitors.
(3) Tolerogenic Peptide. Kang et al. [27] reported that splenic
dendritic cells (DCs) captured the subcutaneously injected
low-dose peptide (three times with H4 (71–94) peptide
(1μg/mouse) in every 2 wk.), which is autoepitope for
lupus nephritis-inducing Th cells in murine and human
lupus and shows cross-reactively recognized by autoimmune
Th cells and B cells, rapidly and expressed a tolerogenic
phenotype in lupus-prone 12-week-old female SNF1 hybrids
but prenephritic. The DC of the tolerized animal, espe-
cially pDC, produced increased amounts of TGF-β,b u t
diminished IL-6 on stimulation via the TLR-9 pathway
by nucleosome autoantigen and other ligands; those pDC
blockedlupusautoimmunediseasebysimultaneouslyinduc-
ing autoantigen-speciﬁc Treg and suppressing inﬂammatory
Th17 cells that inﬁltrated the kidneys of untreated lupus
mice. Thus, the H4 (71–94) peptide tolerance therapy that
preferentially targets pathogenic autoimmune cells could
spare lupus patients from chronically receiving toxic agents
or global immunosuppressants and maintain remission by
restoring autoantigen-speciﬁc Treg cells.
2. Future of Balance Shift of
Th1 (IFN-γ)/Th2 (IL-4) andImmunogenic
DCs(IFN-α/β)/Tolerogenic DCs (TNF-α)
Therearetwomainstreamsofthisreviewintermsofbalance
shit from [I] Th1 to Th2 cells and from [II] immunogenic
(IFN-α/β)totolerogenic(TNF-α)DCs,buttheformerseems
to be more realistic.
[I] Therapy by Th1/Th2 Balance Shift for Clinical Use. Main
issues of this review is balance shift from Th1 to Th2
or alteration of Th1/Th2 ratio by targeting IFN-γ,b u t
not costimulation blockade. For this purpose, gene therapy
seems to be suitable compared to bioactive cytokines or
antibodies against cytokines.
The number of naked/plasmid DNA (18.3%), aden-
ovirus (24.9%) and retrovirus (21.7%) studies has dramat-
ically increased among all gene therapy in clinical trials
(www.wiley.co.uk/genmed/clinical, 2007) [133]. Addition-
ally, the coverage of indications targeted in preclinical and
clinical studies using plasmid DNA is broad-covering cancer,
infectious and noninfectious diseases in both the prophy-
lactic vaccine setting as well as a therapeutic setting. The
nonviral plasmid DNA approach is particularly attractive
due to safety, versatility, and ease of preparation [88]. Also,
compared to viral vectors, it has the beneﬁt of not inducing
immunogenic reactions against components of the vector
itselfupon administration topatients[134].Thisprocesscan
be adapted by other academic centers for human or large
animal clinical trials with cost-eﬀectiveness [135].
Gene transfer oﬀers numerous advantages for the in vivo
delivery of cytokines or their receptors for immunother-
apeutic use [136–138]. Actually, there are a lot of trial12 Journal of Biomedicine and Biotechnology
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Figure 5: Cytokine targeted therapy will be expected to clinical application, but more detailed examination of side eﬀects (e.g., development
of infections, cancer, allergic diseases, and autoimmunity) is required. Clinical application to lupus must be based on their safety proﬁle,
adverse eﬀects, risks, and advantages. Likewise, in this analysis we oﬀer speciﬁc recommendations, based on evidence, for the best, is
Th1/TH2 balance shift in vivo by using IL-4 gene therapy.
of gene therapy in other autoimmune diseases (e.g., T1D,
rheumatoid arthritis: RA) in model animals and in human
with RA [139]. The ﬁrst human trial for RA began in 1996
[140]. Clinical trials for RA have been initiated (phase II).
The ﬁrst evidence of possible clinical responses to gene
transfer was published in 2008 [141]. Plasmid DNA is
superior to viral vectors for direct gene transfer into adult
mouse skeletal muscle [142].
Still in the experimental phase, gene therapy in lupus
promises to correct the aberrant immunological response
without the numerous side eﬀects of the currently used
immunosuppressant medications in lupus [143]( Figure 5
and Table 1). Some study indicated undesirable side eﬀects
such as the impaired response to T-cell-depend and T-cell-
independent antigens, increased susceptibility for infectious
diseases. In addition, IL-5 suppresses lupus nephritis, but
it promotes B-cell lymphoma later. Moreover, IL-4 and IL-
5 may have a possibility to increase susceptibility to Th2
diseases (e.g., allergic rhinitis, asthma). Thus, despite its
promise, gene therapy is a young ﬁeld and a variety of
questions must be addressed in lupus [78]. These points are
needed to clarify.
[II] Therapy by Induction of Tolerogenic DCs for Clinical Use.
Banchereau and Pascual [26] have proposed an extension of
the Th1-Th2 (inﬂammation-allergy) paradigm [110], which
integrates autoimmune responses, by two sets of opposite
vectors, that is, TNF-α-IFN-α/β and IL-4-IFN-γ. The sum
of the cytokines yields an equilibrium point, which allows
protectiveimmunitywhencytokinesareequal.Thisdynamic
systemcanaccommodatetheprevalenceofeithercytokineto
a certain extent. However, when one of the cytokines prevails
beyond a certain threshold, the equilibrium point moves
into a zone of immunopathology, such as autoimmunity,
allergy,orinﬂammation.Thus,whentheTNFprevails,TNF-
α-mediated autoimmunity such as arthritis will occur. When
the IFN-α/β vector prevails, IFN autoimmunity such as SLE
will occur. This might be due to increased bioavailability of
one cytokine or decreased bioavailability of the other one.
The unabated production of a given cytokine will aﬀect
the cells of the immune system and most particularly DCs.
Thus, IFN-α/β-stimulated DCs will polarize naive T cells
diﬀerently than TNF-stimulated DCs.
Also, Banchereau and Pascual [26] claimed that the basic
genetic alterations leading to IFN-α/β overproduction and B
celltolerancebreakdowninSLEandestablishmentoftherole
of other cells like neutrophils, TFh cells, and Tr1 cells in the
pathogenesis of human SLE for new avenues of treatment.
Whether, like TNF antagonists, which have brought consid-
erable relief to RA patients, IFN antagonists will bring relief
to SLE patient. Blocking of IFNα/β (antagonists, balance
shift by TNF) including their side eﬀects and safety is largely
unknown.
3. Conclusions
Simple, eﬀective,easy and safe methods with less side eﬀects
in vivo may be required for preventive intervention.
(1) Cytokine-targeted gene therapy can be applied
to clinical use as suggested by Piccirillo and
Prud’homme [71]. Also this seems to be realistic
rather than targeting proinﬂammatory versus immu-
nosuppressive cytokine proﬁles. Naked DNA method
may be suitable for therapy as shown in Table 1.
(2) Prud’homme suggested that genes encoding TGF-
β1, IL-4, and IL-10 are most frequently protective in
lupus[12,81],butIL-4expressingplasmidDNAmayJournal of Biomedicine and Biotechnology 13
Table 1: Several gene therapies in lupus model mice.
Route Vector Model Eﬀect mechanism/(evidence) (Reference)
Cytokine
IL-4 i.p naked DNA B/WF1 + Balance shift from Th1 to Th2 [68]
IL-2 i.m. naked DNA MRL lpr/lpr −∗ Enhanced autoantibodies production [88]
IL-2 oral naked DNA MRL lpr/lpr + Restoration of T cell response, and suppression of
autosntibody response [89]
IL-2 i.p. vaccinia virus MRL lpr/lpr + Normalization of T cell population [90]
IL-12 i.m. naked DNA MRL lpr/lpr + Cytokine balance skewed towards Th1 [77]
TGF-β1i . m . n a k e d D N A MRL lpr/lpr + Suppression of function of CD4 (Th1,Th2), CD8 T,
B and macrophages. [88]
TGF-β1o r a l n a k e d D N A MRL lpr/lpr − No eﬀect [89]
IL-18 i.m. naked DNA MRL lpr/lpr + Elimination of IL-18 by induction of auto-anti-IL-18
antibody [82]
IL-12/IL-18 i.m. naked DNA MRL lpr/lpr + Presumably elimination of IL-12/IL-18 induction of
anti-IL-12/IL-18 antibodes [87]
Blockade
IFN-γR/Fc∗ i.m. naked DNA MRL lpr/lpr + IFN-γ blockade [80]
CTLA-4/IgG i.m. adenovirus MRL lpr/lpr + costimulatory blockade [92]
CTLA-4/Ig i.v. adenovirus B/WF1 + costimulatory blockade [93]
CTLA-4/CD40 i.m. AAV B/WF1 + costimulatory blockade [94]
PD-L1/anti-B7h i.m. adenovirus BXSB + Negative costimulatory blockade [95]
TACI i.v. adenovirus
B6.lpr/lpr
B/WF1
MRL lpr/lpr
−
±
±
Blys blockade [103]
Tβ-ExR i.v. adenovirus MRL/MpJ
Tnfrsf6lpr +T G F - β blockade [104]
∗worsen, ±:l e s se ﬀective, AAV: adeno-associared virus.
be advantageous compared to other two cytokines as
discussed in each section. Also, the major activity of
IL-18 is the induction of Th1 cells in the presence of
IL-12, and IL-12 without IL-18 has an independent
pathway to induce Th1 response [144], suggesting
complexity of targeting those cytokines. Blocking
of costimulation in antigen presenting process and
elimination of B cells including IL-6 are eﬀective, but
those therapies may severely compromise immune
responsiveness in general.
(3) Van Raalte et al. [4] have reported that despite excel-
lent eﬃcacy in terms of immunosuppression, gluco-
corticoid (GC) therapy is hampered by their notori-
ous metabolic side eﬀect proﬁle. Thus, current trials
to segregate GC’s anti-inﬂammatory and metabolic
actions, are currently being developed. Actually, they
have reported that despite excellent eﬃcacy in terms
of immunosuppression, glucocorticoid therapy is
hampered by their notorious metabolic side eﬀect
proﬁle. Thus, current trials to segregate GC’s anti-
inﬂammatory and metabolic actions, are currently
being developed. On the other hand, compared to
glucocorticoids, cytokine targeted therapy has some
merit, since side eﬀects such as increased metabolic
action may be less in cytokine therapy. Combination
of the use of immunosuppressants and cytokine
targeted therapy also seems likely.
(4) Balance shift from immunogenic to tolerogenic DCs
by targeting IFNα/β together with normalization of
Treg cell function in individuals with SLE has the
potential to lead to remission of this autoimmune
disease. However, there are a few information about
the IFNα/β therapy and complicated interaction of
DCs and Treg cells for balance shift. Moreover,
the information of side eﬀects is totally lacking.
Thus, further studies are needed to accumulate the
information for therapy.
(5) Finally, for the clinical application, we have to
remind that the data obtained from model mouse
are not simply applicable for human with SLE
(species diﬀerence). For example, Horwitz [106]h a s
stressed to distinguish human lupus from mouse
lupus, since in mice the course of the disease is
steadily downhill and fatal whereas human disease
is cyclic and characterized by exacerbations and
remission. In addition, several murine lupus models
other than B/WF1 exist and they can be divided into
spontaneous, congenic, and engineered models as
follows [145]. The best known spontaneous models
arise on New Zealand Black (NZB), New Zealand
White (NZW), MRL, BXSB, and SWR backgrounds.
Hybrids of some of these background strains, like
the NZB/W F1, NZM2410, and the SWR/NZB F1
developANA,glomerulonephritis,andotherfeatures14 Journal of Biomedicine and Biotechnology
of human disease. The lpr (Fas) or gld (FasL)
m u t a t i o n so nt h eM R Lb a c k g r o u n dg i v er i s et o
mice with features of human lupus. However, degree
of lymphoproliferation that occurs in these mice
is not found in humans. Additionally, MRL-lpr/lpr
mice spontaneously develop arthritis, and it displays
more features of RA than of the arthropathy seen
in human SLE. Conversely, humans carrying muta-
tions in the Fas/FasL genes do not develop SLE.
The Yaa mutation, which accelerates disease on the
BXSB background, is due to a translocation of the
TLR7 gene into the Y chromosome, explaining the
predominantly male predisposition to disease in this
particular model [146, 147], which is at striking
diﬀerencewiththe9:1femaletomaleratioinhuman
SLE.
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